<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03181477</url>
  </required_header>
  <id_info>
    <org_study_id>Glio-SIB-Up</org_study_id>
    <nct_id>NCT03181477</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas</brief_title>
  <acronym>Glio-SIB-Up</acronym>
  <official_title>Multicenter Phase II Study Evaluating the Efficacy of Radiotherapy With Modulation Intensity and Integrated Boost (SIB-IMRT) at the Dose of 80Gy, Associated With Chemotherapy by Temozolomide in the Treatment of Adult Glioblastomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioblastoma (GBM) is the most aggressive and most frequent brain tumour. Approximately four
      people per 100,000 inhabitants are diagnosed with this disease every year. The standard
      treatment comprises surgical resection (whenever possible), normofractionated radiotherapy at
      a dose of 60Gray (Gy) and temozolomide (TMZ). Median overall survival in these patients is
      14.6 months [13.2-16.8].

      In a previous phase I clinical trial, dose escalation tolerance using simultaneous-integrated
      boost intensity-modulated radiation therapy (SIB-IMRT) technic has been evaluated. The
      investigator demonstrated that SIB-IMRT until a dose of 80Gy in 32 daily fractions,
      associated with TMZ is feasible and well tolerated by patients with glioblastoma.

      The aim of this present phase II clinical trial is to evaluate the overall survival at 18
      months for patients with glioblastoma receiving TMZ, according to standard protocol,
      associated to radiotherapy delivered at 80Gy using SIB-IMRT technic. The first planning
      target volume (PTV), including oedema and tumour highlighted on T2 flair magnetic resonance
      imaging (MRI) sequences, will receive 60.8Gy in 32 daily fractions. The second PTV, including
      tumour highlighted on T1 MRI sequences, will receive 80.0Gy in 32 daily fractions.

      Secondary objectives are tolerance, survival free progression and quality of live
      evaluations.

      Sixty seven patients will be enrolled in this present trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2017</start_date>
  <completion_date type="Anticipated">December 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Glioblastoma, Adult</condition>
  <arm_group>
    <arm_group_label>radiotherapy + chimiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Radiotherapy of 80 GY + Chemotherapy (Temozolomide)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy of 80 GY + Chemotherapy (Temozolomide)</description>
    <arm_group_label>radiotherapy + chimiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged from 18 to 70 years old.

          -  Patients with a unifocal Glioblastoma (grade IV astrocytoma in the World Health
             Organization (WHO) classification) with postoperative macroscopic residue after biopsy
             or resection alone.

          -  Location of the tumor or residual tumor, detected by Magnetic Resonance Imaging (MRI)
             sequences T1 gadolinium, more than 1cm from the optic chiasm

          -  Diagnosis confirmed by pathology.

          -  Time from surgery (if performed) and the start of radiation therapy less than 6 weeks.

          -  performance status 0 or 1 in the WHO classification.

          -  methylation status of the MGMT promoter gene requested

          -  blood count: Neutrophil more than 1500/mm3 Platelets more than 100 000/mm3

          -  Liver function test Bilirubin less than 1,5 times upper limit transaminases than 3
             times upper limit

          -  patient informed and informed consent signed

          -  Possibility to trat by radiation withintensity modulated (fixed beams modulated or
             rotational modulation (TomoTherapy, dynamic arctherapy)) strictly respecting the
             constraints to organs at risk (Crystalline: 8 Gy max, Posterior chamber of the eye: 45
             Gy max , optic nerve: 54 Gy max, chiasm: 54 Gy max, brain Stem: 2% 58 Gy D2 &lt;64 Gy,
             Dmax &lt;69 Gy spinal cord: 46 Gy max, healthy brain (brain - PTV): 60 Gy max 33%, 50 Gy
             to 50% and D100 &lt;45 Gy to the brain in toto).

          -  The patient must be affiliated to a social security scheme.

        Exclusion Criteria:

          -  Other histological &quot;Glioblastoma&quot;.

          -  Excision macroscopically complete individualized on postoperative MRI.

          -  Patient unable to give consent.

          -  A patient with against-indication to performed MRI (pacemaker, uncontrollable
             claustrophobia ...).

          -  The patient must not have received radiation therapy or previous chemotherapy for this
             condition.

          -  Other neoplasia unstabilized and / or treated for less than 5 years.

          -  Patient already included in another clinical trial with an experimental molecule.

          -  Inability to submit to medical monitoring testing for geographical, social or
             psychological.

          -  Pregnancy or breastfeeding

          -  Private Person of liberty under supervision or under curatorship

          -  No affiliation to a social security scheme or medical state aid or the universal
             medical coverage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gilles TRUC</last_name>
    <phone>+33 3 80 73 75 00</phone>
    <email>gtruc@cgfl.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie REDERSTORFF</last_name>
    <phone>+33 3 45 34 81 16</phone>
    <email>erederstorff@cgfl.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patrick Dr Bontemps, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21850</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Gille TRUC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie et de radiothérapie</name>
      <address>
        <city>Mâcon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Valérie Dr POUCHARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>valérie Dr Bernier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Delphine Dr Antoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Cancérologie Des Dentellières</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>niolas Dr BLANCHARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2017</study_first_submitted>
  <study_first_submitted_qc>June 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase II</keyword>
  <keyword>Radiotherapy with SIB-IMRT</keyword>
  <keyword>Tomozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

